2025-01-18 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

This report analyzes Eli Lilly and Co. (LLY), a leading pharmaceutical company, based on the provided data.

**1. Performance Comparison and Divergence:**

LLY's cumulative return (516.30%) significantly outperforms the S&P 500 (VOO) cumulative return (118.37%). The raw difference in cumulative returns is 397.9%, placing it at the 64.1st percentile of historical divergence based on a range of -25.2% to 634.6%.  This indicates LLY's substantial outperformance relative to the broader market over the period considered.  The provided CAGR data further reinforces this strong performance, with consistently high growth rates exceeding 100% in several periods.


**2. Recent Price Movement:**

* **Closing Price:** $725.72
* **5-Day Moving Average:** $754.49
* **20-Day Moving Average:** $773.16
* **60-Day Moving Average:** $796.70

The current closing price is below all three moving averages, suggesting a potential short-term downtrend.  This is consistent with the negative divergence observed in the next section.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 31.34 - This indicates the stock is in oversold territory, potentially suggesting a bounce is due.

* **PPO (Percentage Price Oscillator):** -0.51 -  A negative PPO suggests bearish momentum.

* **Delta_Previous_Relative_Divergence:** -10.5% - This negative value indicates a recent decline in relative performance compared to the S&P 500.  This is consistent with the closing price being below the moving averages.

* **Expected Return:** 151.1% - This represents a significant projected outperformance compared to the S&P 500 over the long term (2+ years) assuming continued similar trends.  However, this is based on past performance and doesn't guarantee future returns.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|----------------|
| 2024-10-30 | $1.08   | $11.44B        |
| 2024-08-08 | $3.29   | $11.30B        |
| 2024-04-30 | $2.49   | $8.77B         |
| 2023-11-02 | -$0.06  | $9.50B         |
| 2023-10-30 | -$0.06  | $9.50B (Duplicate Entry?) |

Earnings show significant volatility. While there are periods of high EPS, there's also a notable negative EPS reported.  Revenue remains relatively consistent, with some fluctuation. The duplicate entry for 2023-10-30 and 2024-10-30 needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2024-09-30 | $11.44B     | 81.02%        |
| 2024-06-30 | $11.30B     | 80.80%        |
| 2024-03-31 | $8.77B      | 80.91%        |
| 2023-12-31 | $9.35B      | 80.88%        |
| 2023-09-30 | $9.50B      | 80.42%        |

Revenue is relatively stable, with high and consistent profit margins, indicating strong profitability.

**Capital and Profitability:**

| Quarter    | Equity      | ROE           |
|------------|-------------|---------------|
| 2024-09-30 | $14.24B     | 6.81%         |
| 2024-06-30 | $13.56B     | 21.88%        |
| 2024-03-31 | $12.81B     | 17.51%        |
| 2023-12-31 | $10.77B     | 20.33%        |
| 2023-09-30 | $11.22B     | -0.51%        |


Equity shows growth, but ROE is volatile.  The negative ROE in 2023-09-30 requires further investigation.


**7. Overall Analysis:**

LLY shows a history of exceptional performance significantly outpacing the S&P 500.  However, recent price action and technical indicators suggest a potential short-term downturn. While the long-term outlook remains positive, based on the high projected return, careful consideration is warranted given the volatility in earnings and ROE.  Further investigation into the duplicate earnings entry and the negative ROE is crucial before making any investment decisions.  The current oversold RSI suggests a possible short-term bounce, but the negative PPO and downward price trend warrant caution.  The high profit margins and relatively stable revenue are positive signs.


**8. Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Independent research and consultation with a financial professional are recommended before making any investment decisions.
